Show simple item record

dc.contributor.authordas Nair, Roshan
dc.date.accessioned2022-08-04T10:05:48Z
dc.date.available2022-08-04T10:05:48Z
dc.date.issued2022
dc.identifier.citationGarjani, A., Liu, B. J.-Y., Allen, C. M., Gunzler, D. D., Gerry, S. W., Planchon, S. M., das Nair, R., Chataway, J., Tallantyre, E. C., Ontaneda, D., et al. (2022). Decentralised clinical trials in multiple sclerosis research. Multiple Sclerosis Journal, DOI: 10.1177/13524585221100401en_US
dc.identifier.other10.1177/13524585221100401
dc.identifier.urihttp://hdl.handle.net/20.500.12904/15690
dc.description.abstractRandomised controlled trials (RCTs) play an important role in multiple sclerosis (MS) research, ensuring that new interventions are safe and efficacious before their introduction into clinical practice. Trials have been evolving to improve the robustness of their designs and the efficiency of their conduct. Advances in digital and mobile technologies in recent years have facilitated this process and the first RCTs with decentralised elements became possible. Decentralised clinical trials (DCTs) are conducted remotely, enabling participation of a more heterogeneous population who can participate in research activities from different locations and at their convenience. DCTs also rely on digital and mobile technologies which allows for more flexible and frequent assessments. While hospitals quickly adapted to e-health and telehealth assessments during the COVID-19 pandemic, the conduct of conventional RCTs was profoundly disrupted. In this paper, we review the existing evidence and gaps in knowledge in the design and conduct of DCTs in MS.
dc.description.urihttps://journals.sagepub.com/doi/10.1177/13524585221100401en_US
dc.language.isoenen_US
dc.subjectClinical trialen_US
dc.subjectMultiple sclerosisen_US
dc.subjectResearch designen_US
dc.titleDecentralised clinical trials in multiple sclerosis researchen_US
dc.typeArticleen_US
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US
rioxxterms.versionNAen_US
rioxxterms.typeJournal Article/Reviewen_US
refterms.panelUnspecifieden_US
refterms.dateFirstOnline23/06/2022
html.description.abstractRandomised controlled trials (RCTs) play an important role in multiple sclerosis (MS) research, ensuring that new interventions are safe and efficacious before their introduction into clinical practice. Trials have been evolving to improve the robustness of their designs and the efficiency of their conduct. Advances in digital and mobile technologies in recent years have facilitated this process and the first RCTs with decentralised elements became possible. Decentralised clinical trials (DCTs) are conducted remotely, enabling participation of a more heterogeneous population who can participate in research activities from different locations and at their convenience. DCTs also rely on digital and mobile technologies which allows for more flexible and frequent assessments. While hospitals quickly adapted to e-health and telehealth assessments during the COVID-19 pandemic, the conduct of conventional RCTs was profoundly disrupted. In this paper, we review the existing evidence and gaps in knowledge in the design and conduct of DCTs in MS.
rioxxterms.funder.project94a427429a5bcfef7dd04c33360d80cden_US


This item appears in the following Collection(s)

Show simple item record